Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd.

June 25, 2015 08:00 ET

Ventripoint Announces Development of New VMS™ Products and Enhanced Capabilities as Featured at ASE 2015

VMS to be Upgraded to do Volume Measurements on all 4 Chambers of the Heart

SEATTLE, WASHINGTON--(Marketwired - June 25, 2015) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased to announce that a new platform design of the VMS™ workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus™, was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week.

VMS-Plus will replace the current cart-based platform and has features that include improved ergonomics, less physical space to operate, and increased portability. The VMS-Plus was well received at the ASE 2015 by those individuals familiar with the original VMS machine. They particularly liked the sleek design and the enhanced feature being tested that corrects for patient movement that may occur during the exam. This feature has been the single most requested enhancement from our customer base.

"It simply is not practical to expect that all 2D images will be captured without some patient movement, and when the movement is significant the exam may need to be repeated." stated Jim Bodtke, Vice President, Clinical Affairs & Development. "This enhancement to our product not only improves our customers' experience, but may also allow the VMS to be used on a greater number of patients that have difficulty remaining still throughout the exam."

Development Update

With the recent clearance in the United States of the Right Ventricle (RV) database for all patients where RV analysis is desired or warranted (see News Release, May 26, 2015), the Company has been encouraged to make commercially available databases for the other 3 chambers of the heart. While RV volume measurements are valuable in chronic heart failure, there is a large demand for accurate volume measurements of the Left and Right Atria for treating patients who have pacemakers as well as those with heart failure. The VMS is ideally suited to provide these measurements quickly and with the accuracy of MRI, which remains the gold standard for cardiac chamber volumes but is not done routinely due to cost and convenience.

A first look at the process for VMS volume quantification in all 4 chambers of the heart was also exhibited at ASE 2015. This feature was demonstrated recently at one of China's most prestigious cardiac care hospitals, Anzhen Hospital in Beijing, where it was very well received and recognized as addressing an emerging need. This demonstration makes the VMS the world's first technology to provide 3D volume quantification of all 4 heart chambers using 2D ultrasound, which is the most common method for cardiac exams in the world. The VMS technology can also provide analysis of 3D ultrasound images of the heart with the same accuracy as MRI. This is a benefit to the market as current 3D ultrasound technology is widely accepted as inaccurate in calculating volumes. Initially thought to be years away, Ventripoint is hopeful that all development will be completed for the 4 chamber feature within this year, followed by regulatory clearances and commercial release.

In addition to the new workstation design for the VMS-Plus, another new VMS platform has been created for Ventripoint's product line. This product has been designed specifically for emerging markets in order to offer great value in a very compact design. The new VMS product is expected to be Ventripoint's lead-in to emerging markets where low-cost, 2D-ultrasound equipment is prevalent. The Company is currently seeking manufacturing partners for this model.

Commenting on the recent developments, Ventripoint's President and CEO, Dr. George Adams, stated "All of the recent developments have occurred years ahead of schedule, with some advances previously thought impossible. This not only shows dedication to our customers and their patients, but also our shareholders as we are greatly increasing the value and potential of the Company."

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to help physicians monitor patients with heart disease, the leading cause of death globally. VMS is the first cost-effective and accurate tool for measuring right ventricle heart function. The Company has a suite of applications for all major heart diseases, which may be used with multiple imaging modalities, including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information